Literature DB >> 25391543

Predictors of the response to treatment in acute lupus hemophagocytic syndrome.

H Takahashi1, H Tsuboi1, I Kurata1, H Takahashi1, S Inoue1, H Ebe1, M Yokosawa1, S Hagiwara1, T Hirota1, H Asashima1, S Kaneko1, H Kawaguchi1, Y Kurashima1, H Miki1, N Umeda1, Y Kondo1, H Ogishima1, T Suzuki1, I Matsumoto1, T Sumida2.   

Abstract

OBJECTIVE: The objective of this paper is to identify predictors for the response to treatment of acute lupus hemophagocytic syndrome (ALHS).
METHODS: We reviewed seven cases with ALHS admitted to our hospital and published ALHS cases identified in the 2001-2014 Medline database, and then conducted univariate and multivariate analyses to identify predictors for the response to treatment.
RESULTS: Review of our cases showed a significant and negative correlation between serum ferritin and anti-DNA antibody (p = 0.0025). All three patients treated with cyclosporine A (CsA) were considered responders despite high serum ferritin and corticosteroid resistance. We also reviewed 93 patients with ALHS identified in 46 articles. Multiple logistic regression analysis identified C-reactive protein (CRP) (OR 0.83, p = 0.042) and hemoglobin (OR 1.53, p = 0.026) measured at diagnosis of ALHS as significant predictors of the response to corticosteroid monotherapy. Moreover, among 32 patients treated with CsA, serum ferritin was significantly higher in CsA responders (12163 ± 16864 µg/l, n = 22) than in non-responders (3456 ± 6267/µg/l, p = 0.020, n = 10). Leukocyte count was significantly lower in the CsA responders (1940.0 ± 972.3/µl) than in the non-responders (3253 ± 2198/µl, p = 0.034).
CONCLUSION: Low CRP and high hemoglobin can predict a positive response to corticosteroid monotherapy while high serum ferritin and low leukocyte count can predict a positive response to CsA in patients with ALHS and therefore, when corticosteroid monotherapy is not effective in such cases, CsA could be the first choice of an additional immunosuppressive agent.
© The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Response to therapy; acute lupus hemophagocytic syndrome; corticosteroids; cyclosporine A

Mesh:

Substances:

Year:  2014        PMID: 25391543     DOI: 10.1177/0961203314559086

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  4 in total

1.  Arthritis and use of hydroxychloroquine associated with a decreased risk of macrophage activation syndrome among adult patients hospitalized with systemic lupus erythematosus.

Authors:  E M Cohen; K D'Silva; D Kreps; M B Son; K H Costenbader
Journal:  Lupus       Date:  2018-02-16       Impact factor: 2.911

2.  Macrophage activation syndrome in systemic lupus erythematosus: a multicenter, case-control study in China.

Authors:  Ai-Chun Liu; Yue Yang; Meng-Tao Li; Yuan Jia; Sheng Chen; Shuang Ye; Xiang-Zong Zeng; Zhao Wang; Jin-Xia Zhao; Xiang-Yuan Liu; Jian Zhu; Yan Zhao; Xiao-Feng Zeng; Zhan-Guo Li
Journal:  Clin Rheumatol       Date:  2017-04-13       Impact factor: 3.650

3.  Intractable Hemophagocytic Syndrome Associated with Systemic Lupus Erythematosus Resistant to Corticosteroids and Intravenous Cyclophosphamide That Was Successfully Treated with Cyclosporine A.

Authors:  Hirofumi Toko; Hiroto Tsuboi; Naoto Umeda; Fumika Honda; Ayako Ohyama; Hidenori Takahashi; Saori Abe; Masahiro Yokosawa; Hiromitsu Asashima; Shinya Hagiwara; Tomoya Hirota; Yuya Kondo; Isao Matsumoto; Takayuki Sumida
Journal:  Intern Med       Date:  2018-05-18       Impact factor: 1.271

Review 4.  The Use of Cyclosporine A in Rheumatology: a 2016 Comprehensive Review.

Authors:  Cecilia Beatrice Chighizola; Voon H Ong; Pier Luigi Meroni
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 10.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.